ISRAEL Law and Practice Contributed by: David Gilat and Matan Kovacs, Gilat, Bareket & Co, Reinhold Cohn Group
• the adequacy and good faith of the proposed representatives. Over the years, there have been many class action proceedings in the life sciences/pharma sector, litigating claims such as misrepresenta - tion of side effects, failure to disclose expira - tion dates, misrepresentation of ingredients, and misclassification of preparations.
142 CHAMBERS.COM
Powered by FlippingBook